Skip to Content

What is the difference between Cyltezo and Humira?

Medically reviewed by Last updated on Oct 17, 2017.

Official Answer


Cyltezo (adalimumab-adbm) is a biosimilar to Humira (adalimumab). However, Cyltezo is not an interchangeable product with Humira; the physician must write a prescription specifically for Cyltezo.

Both are anti-TNF-α monoclonal antibodies. A biosimilar, according to the FDA, is a biological product that is highly similar to an FDA-approved biological product, known as a reference product (in this case Humira), and has no clinically meaningful differences in terms of safety and effectiveness.

Both biologics are used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. 

See also:

Related Drug Information

Other Medical Questions